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Abstract
Background: Tracking the dissemination of specific Mycobacterium tuberculosis (Mtb) strains using genotyped Mtb
isolates from tuberculosis patients is a routine public health practice in the United States. The present study proposes a
standardized cluster investigation method to identify epidemiologic-linked patients in Mtb genotype clusters. The study
also attempts to determine the proportion of epidemiologic-linked patients the proposed method would identify
beyond the outcome of the conventional contact investigation.
Methods: The study population included Mtb culture positive patients from Georgia, Maryland, Massachusetts and
Houston, Texas. Mtb isolates were genotyped by CDC’s National TB Genotyping Service (NTGS) from January 2006 to
October 2010. Mtb cluster investigations (CLIs) were conducted for patients whose isolates matched exactly by
spoligotyping and 12-locus MIRU-VNTR. CLIs were carried out in four sequential steps: (1) Public Health Worker
(PHW) Interview, (2) Contact Investigation (CI) Evaluation, (3) Public Health Records Review, and (4) CLI TB Patient
Interviews. Comparison between patients whose links were identified through the study’s CLI interviews (Step 4)
and patients whose links were identified earlier in CLI (Steps 1–3) was conducted using logistic regression.
Results: Forty-four clusters were randomly selected from the four study sites (401 patients in total). Epidemiologic links
were identified for 189/401 (47 %) study patients in a total of 201 linked patient-pairs. The numbers of linked patients
identified in each CLI steps were: Step 1 - 105/401 (26.2 %), Step 2 - 15/388 (3.9 %), Step 3 - 41/281 (14.6 %), and Step
4 - 28/119 (30 %). Among the 189 linked patients, 28 (14.8 %) were not identified in previous CI. No epidemiologic links
were identified in 13/44 (30 %) clusters.
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Conclusions: We validated a standardized and practical method to systematically identify epidemiologic links among
patients in Mtb genotype clusters, which can be integrated into the TB control and prevention programs in public
health settings. The CLI interview identified additional epidemiologic links that were not identified in previous CI.
One-third of the clusters showed no epidemiologic links despite being extensively investigated, suggesting that some
improvement in the interviewing methods is still needed.
Keywords: Tuberculosis, Epidemiology, Genotype, Cluster investigation, MIRU-VNTR, Spoligotype, Contact investigation,
Surveillance
Background
Tuberculosis (TB) contact investigation (CI) is a disease
control strategy that performs a crucial role in understand-
ing the most relevant epidemiologic factors influencing TB
transmission between individuals [1]. In addition to CI,
tracking the dissemination of specific Mycobacterium
tuberculosis (Mtb) strains in populations is an important
tool used to understand TB transmission dynamics [2].
For over 20 years, investigators have been discovering and
utilizing genetic elements of the Mtb genome as molecular
genotype markers [3]. The Mtb genotyping methodologies
include utilizing the direct repeat locus-based spacer
oligonucleotide typing (spoligotyping) [4, 5] and mycobac-
terial interspersed repetitive unit-variable number of tan-
dem repeat (MIRU-VNTR) typing [6]. These genotyping
techniques have been routinely used by the Centers for
Disease Control and Prevention (CDC) since 2004 [7].
United States (US) public health departments evaluate
persons having known contact with infectious TB pa-
tients to identify and treat individuals for whom TB
transmission results in active TB disease or latent TB
infection (LTBI). Because of the difficulty in identifying
and assessing all individuals potentially infected by a
given TB patient, CIs provide an incomplete picture of
TB transmission. The investigation of TB transmission
has been enhanced with the application of Mtb genotyping
[8]. When Mtb genotyping is conducted routinely on all
or nearly all Mtb isolates from a given jurisdiction, persons
with isolates that have the same genotype are termed
“clustered” and are suspected of being transmitted re-
cently. Individuals with Mtb isolates that have unique
genotypes are termed “non-clustered”. TB development
in these persons is considered to be due to reactivation
of previously acquired LTBI, recent transmission with
someone who was not genotyped, transmission from a
person outside the 3-year surveillance time window or geo-
graphic area, or relapse of a prior episode of TB disease [9].
Genotypic data can facilitate the detection of previously
unsuspected transmission [10–12]. Furthermore, when TB
patients are identified as epidemiologic-linked through CI,
TB transmission can be confirmed or refuted by matching
(concordant) or discrepant (discordant) genotypes, respect-
ively [13]. Due to issues concerning the discriminatory
power of the genotyping techniques used [8, 14, 15], as well
as the endemic level of genotype in a jurisdiction [16], it
cannot be assumed that TB patients with matching geno-
types result from the same chain of transmission. However,
transmission between TB patients with matching genotypes
can be verified by detecting epidemiologic linkages, which
include: timing, interactions, or relationships among the
persons [17]. Epidemiologic investigations of TB patients
having genotypically matched Mtb isolates can uncover
transmission venues and epidemiologic links between
persons not identified by routine CI [11]. Public health
investigators refer to these additional efforts as cluster
investigations (CLI). The current study implements a
standardized process for conducting CLI systematically
and validates the application of this process to a set of




Mtb culture-positive patients from four study sites re-
ported to the CDC from January 2006 to October 2010,
whose Mtb isolates were genotyped by CDC’s National
TB Genotyping Service (NTGS), were evaluated for Mtb
clustering. Study sites, Georgia (GA), Maryland (MD),
Massachusetts (MA) and Houston (HOU), Texas, were
members of the Tuberculosis Epidemiologic Studies
Consortium, a consortium of US sites funded by CDC
to conduct TB epidemiologic research [18]. All sites
except Texas evaluated TB patients for Mtb clustering
in counties throughout the state. In Texas, only TB pa-
tients reported in the City of Houston jurisdiction (HOU)
were evaluated. The study was approved by Institutional
Review Boards at CDC and each study site.
TB cluster selection process
Mtb isolates from all patients were characterized by
NTGS using spoligotyping and 12-locus MIRU-VNTR
(MIRU12). Each unique combination of spoligotype and
MIRU12 results is assigned a “PCRType” [19]. Clusters
were defined as two or more TB patients with the same
PCRType in a given public health jurisdiction (county or
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HOU) during the study period. Clusters were eligible for
random sampling selection if the cluster consisted of at
least three TB patients residing in the same given public
health jurisdiction, whose TB status were reported between
January 1, 2006 and the time of cluster evaluation. Eligible
clusters for each of the four sites (see above) were assigned
to three priority groups (low, medium, and high priority)
based on their calculated log-likelihood ratio (LLR: <1.00,
1.00-5.79, and ≥5.80, respectively) associated with the
public health cluster priorities [20, 21]. After reviewing
the geospatial scores [21], initial expert panel rankings,
and cluster investigation findings, the CDC statistician
and the expert panel determined the log-likelihood ra-
tio (LLR) cut-points that were associated with high-,
medium-, and low-priority clusters in our surveillance
data. Clusters were then randomly selected from each
group. In total, 44 clusters (11 per site) were selected
for further investigation. Details of sample size conside-
rations and the sample selection strategy are provided
in Additional file 1.
Epidemiologic links
An epidemiologic link was defined as relationships between
two TB cases within a cluster who were determined to have
likely shared air space while at least one of the cases had
active TB disease. Epidemiologic links were considered
definite if two cases named each other as a contact or were
identified as having been in the same place at the exact
same time; probable if the cases were in same place in the
same timeframe (same week); and possible if the cases
were in the same place possibly at the same time (month or
season). A homogeneous attribute was defined as a single
epidemiologic characteristic describing all patients in a
given cluster.
Cluster investigation
Beginning in late 2009, TB surveillance data for all sub-
jects were obtained using the Report of Verified Case of
Tuberculosis (RVCT) [22] through collaborations with
local public health staff. The subjects were part of the
selected clusters in the data routinely collected by the
CDC’s National Tuberculosis Surveillance System.
In coordination with local TB programs, CLIs for each
selected cluster were conducted to determine whether
TB patients in a given cluster had epidemiologic-linkages.
Patients in selected clusters who were identified after
cluster selection occurred were also investigated. A study
protocol was developed whereby CLIs were carried out
in a stepwise fashion (Fig. 1 and Additional file 2-CLI
Instruments):
Step 1: Public health worker interview
Public health workers (public health supervisors,
case managers, disease intervention specialists or
contact investigators) for each clustered TB patient
were contacted by study staff and asked whether they
Fig. 1 Steps for cluster investigation
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were aware of any epidemiologic links between the
patients. If epidemiologic links were identified between
two or more patients in the cluster, that information
was documented. The public health workers could
use any available documents as mental reminders
during the interview.
Step 2: Contact investigation evaluation
In coordination with local TB program staff, contact
investigation records of patients in clusters were
collected and reviewed to determine whether
epidemiologic linkages to other TB patients were
identified during the routine CI. For each patient
evaluated, the number of contacts evaluated and
the number of contacts with newly identified LTBI,
previously diagnosed LTBI and active TB disease
were documented.
Public health worker interviews and contact
investigation evaluations were carried out on each
study patient except when no public health worker
could be contacted or when contact investigations
were not done. After each single epidemiologic link
was established, investigations routinely continued
to explore additional epidemiologic links between a
patient and other patients in a given cluster.v
Step 3: Review of public health records
If no epidemiologic links were identified in Steps 1
and 2, TB patients’ public health records which
contain documentation of any intake or follow-up
patient interviews conducted by the health department
were reviewed to determine whether there were
documented epidemiologic links to other TB patient(s),
and whether location-based relationships existed
between patients in the same cluster (e.g. residential,
social, or medical settings).
Step 4: CLI TB patient interviews
If no epidemiologic links were identified between
patients in a cluster from CLI Steps 1–3, patients
were contacted and interviewed after verbal consent
was obtained using a pilot-tested interview instrument
(Additional file 2), beginning with the most recently
diagnosed subject. The interview instrument was
designed to facilitate identification of epidemiologic
linkages to other TB patients. For every epidemiologic
link identified, estimated dates of symptom onset,
relationship between patients, the most frequent
patient-pair setting where transmission may have
occurred, and the CLI step where the link was
identified were documented.
Epidemiologic links were investigated only if both
patient-isolates were genotyped. CLI study instruments
(Additional file 2) contained items designed to collect
details of the study patients’ frequently visited
locations, which could be evaluated as possible
venues for transmission.
Data management and analysis
Study data were entered into a Microsoft Access 2003
(Redmond, WA) database by site staff and merged for
analysis by the data coordinating center at the Texas site.
National summary data on study PCRTypes (number of
patients and the number of states reporting the given
genotype) were provided by the CDC. To summarize the
characteristics of study clusters, patients in a given cluster
were compared to all other study patients by select demo-
graphic and behavioral characteristics and two-sided P-
values were calculated. Clusters associated with at least
one epidemiologic link were compared to those without
identified epidemiologic link by demographic, behavioral,
clinical and genotypic variables.
Comparison between patients whose linkage was
identified through the study’s CLI interviews (Step 4)
and patients whose linkage was identified earlier in CLI
(Steps 1–3) was conducted using univariate and multiple
logistic regression. Statistical analyses were conducted
using Stata/SE 13.1 (StataCorp LP, College Station, TX).
Results
From 2006 to 2010, there were 62,642 reported TB cases
in the US, reflecting a TB case rate of 4.1 cases/100,000
[23]. During the same time period, study site jurisdictions
reported the following number of TB cases: MD-1239,
MA-1208, GA-2291 and HOU-1315, corresponding to an
average TB rate of 4.4, 3.7, 4.8 and 12.5 cases/100,000, res-
pectively [23]. The proportion of Mtb culture-positive
patients that were genotyped during the study period was
82.1 % for the US and 98.5, 89.9, 84.4 and 85.8 % for MD,
MA, GA and HOU, respectively [19]. From a pool of 132
eligible clusters (MD-25, MA-23, GA-35, HOU-49), 44
clusters (11 clusters from each site) corresponding to
38 distinct PCRTypes were randomly selected for inves-
tigation. Three PCRTypes (PCR00002, PCR00016 and
PCR00017) were investigated in more than one study
jurisdiction (Table 1). Most of the PCRTypes were of
Euro-American (L4) or East Asian (L2) lineage (n = 29
and n = 7, respectively), but one PCRType each was identi-
fied of East African Indian (L3) and Indo-Oceanic (L1)
lineages. PCRTypes found in the study were also seen na-
tionally with a distribution range from one to 46 states.
Three PCRTypes were seen in no US state other than that
associated with the study site during the study period:
PCR06732 (GA), PCR04837 (TX) and PCR04846 (TX).
A total of 401 study patients in the 44 selected clusters
were evaluated by the CLI method. Median cluster size
was six (range 3–33); HOU clusters tended to be larger
than those from other sites (median 10 vs. 6, p = 0.024).
Nineteen clusters (43 %) had only US-born patients and
eight clusters (18 %) contained only foreign-born patients
(Table 2). Certain single epidemiologic profiles describing
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all patients in a given cluster were identified for specific
clusters (Table 2, “Homogeneous attribute” column).
In 401 study patients, 189 (47 %) patients were identi-
fied with epidemiologic links in a total of 201 linked
patient-pairs (Fig. 2), of which 132 (66 %) were definite
linkage strength, 27 (13 %) were probable and 42 (21 %)
were possible epidemiologic links. Screening by a PHW
(Step 1) identified 105/401 (26.2 %) linked patients.
Table 1 Study genotypes
PCRType Cluster(s) Jurisdictions* Lineage† Spoligotype MIRU12 Study cases US cases‡ States with genotype‡
PCR00002 05, 21, 32, 35, 38 5 (GA/MA3/MD) L2 000000000003771 223325173533 44 1619 46
PCR00015 44 1 (GA) L4 777776777760601 224325153323 15 749 43
PCR00016 16, 36 2 (GA/MA) L4 700036777760731 222325143223 29 227 30
PCR00017 25, 43 2 (GA/TX) L4 777776777760601 224325153324 7 139 28
PCR00022 22 1 (MA) L4 777777777720771 225325153323 3 435 42
PCR00036 41 1 (TX) L2 000000000003771 223425173563 8 165 22
PCR00041 28 1 (TX) L1 677777477413771 254326223432 13 1392 46
PCR00044 17 1 (MD) L3 703377400001771 227425113434 5 110 26
PCR00051 39 1 (TX) L4 776037777760771 223125163324 29 164 28
PCR00079 03 1 (MD) L4 777777777760771 223125153324 5 149 30
PCR00169 18 1 (MD) L4 777776777760771 224325124324 4 41 17
PCR00224 11 1 (TX) L2 000000000003771 223325163333 33 116 16
PCR00293 30 1 (GA) L4 777777777760771 223225141324 16 30 3
PCR00497 26 1 (TX) L4 776377777760771 233325153324 10 79 23
PCR00578 13 1 (GA) L4 777776777760771 125325143224 13 43 7
PCR00719 10 1 (TX) L4 777777777760771 223425143322 15 124 23
PCR00724 06 1 (MA) L4 777777777760771 225125113322 3 89 24
PCR00849 23 1 (MA) L4 777777347760471 224315143324 8 39 12
PCR01017 34 1 (MD) L4 776177607760771 224326133324 4 42 17
PCR01034 37 1 (MA) L4 777777777760731 223425123324 3 11 5
PCR01046 07 1 (MA) L4 677777607760771 223226153321 4 58 19
PCR01047 01 1 (MD) L4 777776777760601 223325153322 16 29 5
PCR01201 12 1 (TX) L2 000000000003771 223325173534 32 164 25
PCR01571 31 1 (GA) L2 000000000003771 223225173433 8 32 11
PCR01674 02 1 (MD) L4 700076777760771 225225153326 6 12 3
PCR01872 15 1 (GA) L4 777776777760601 223325153324 3 6 4
PCR01873 40 1 (TX) L4 777776777760601 224325153321 3 28 10
PCR02143 04 1 (MD) L4 777777777720771 225325153322 3 34 16
PCR02397 29 1 (GA) L4 777776777760601 223325153323 11 50 10
PCR02651 19 1 (MD) L4 777777743760771 223215153324 3 15 9
PCR03405 24 1 (MA) L4 776377777760771 232325143324 9 11 2
PCR03412 08 1 (MA) L2 000000000003771 222315173543 6 16 5
PCR03588 42 1 (GA) L4 037776777760601 224325153423 6 17 3
PCR03994 20 1 (MD) L4 777777600060771 224226123311 3 12 2
PCR04200 33 1 (MD) L4 776177400000171 223326133323 4 10 3
PCR04837 27 1 (TX) L4 777776777760601 224315163323 4 5 1
PCR04846 09 1 (TX) L2 000000000003771 223425163333 7 17 1
PCR06732 14 1 (GA) L4 777760377760771 223225153325 6 8 1
*Number of study jurisdictions where the genotype was investigated
†L1: Indo-Oceanic; L2: East Asian; L3: East African Indian; L4: Euro-American; ‡Verified cases of tuberculosis reported by CDC, 2006-2010. MIRU: mycobacterial
interspersed repetitive units; PCR: polymerase chain reaction
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Table 2 Characteristics of study clusters
Cluster PCRType Site Cluster size US-born Male Racea Home-less Epi-linkedb Homogeneous attribute
01 PCR01047 MD 16 94 % 94 % 100 % B 75 % 81 % Blacks (15/16 US-born)
02 PCR01674 MD 6 100 % 50 % 100 % B 0 % 50 % US-born Blacks
03 PCR00079 MD 5 100 % 40 % 100 % B 20 % 40 % US-born Blacks
04 PCR02143 MD 3 100 % 67 % 100 % B 0 % 67 % US-born Blacks
05 PCR00002 MA 10 20 % 90 % 90 % A 10 % 0 % none
06 PCR00724 MA 3 0 % 67 % 67 % B 0 % 0 % Foreign-born (but country mixture)
07 PCR01046 MA 4 25 % 50 % 75 % B 25 % 25 % none
08 PCR03412 MA 6 100 % 100 % 67 % B 17 % 83 % US-born males
09 PCR04846 TX 7 100 % 57 % 100 % B 14 % 0 % US-born Blacks
10 PCR00719 TX 15 53 % 67 % 80 % H 7 % 47 % none
11 PCR00224 TX 33 100 % 85 % 58 % B 24 % 52 % US-born
12 PCR01201 TX 32 94 % 88 % 47 % B 44 % 44 % none
13 PCR00578 GA 13 100 % 77 % 92 % B 31 % 77 % US-born (12/13 Black)
14 PCR06732 GA 6 50 % 67 % 67 % H 0 % 83 % none
15 PCR01872 GA 3 100 % 33 % 100 % B 0 % 0 % US-born Blacks
16 PCR00016 GA 19 95 % 68 % 95 % B 37 % 53 % 18/19 US-born Blacks
17 PCR00044 MD 5 0 % 40 % 100 % B 0 % 60 % Africa-born Blacks
18 PCR00169 MD 4 50 % 25 % 100 % B 0 % 0 % Blacks
19 PCR02651 MD 3 0 % 0 % 100 % B 33 % 33 % Cameroon-born Black females
20 PCR03994 MD 3 100 % 33 % 100 % B 0 % 100 % US-born Blacks
21 PCR00002 MA 4 25 % 75 % 75 % A 25 % 0 % none
22 PCR00022 MA 3 0 % 33 % 67 % H 0 % 0 % Foreign-born (but country mixture)
23 PCR00849 MA 8 88 % 100 % 63 % W 88 % 63 % Males (7/8 US-born, homeless)
24 PCR03405 MA 9 11 % 89 % 100 % W 11 % 78 % White (8/9 Portugal-born)
25 PCR00017 TX 3 100 % 67 % 67 % B 33 % 0 % US-born
26 PCR00497 TX 10 100 % 50 % 100 % B 10 % 20 % US-born Blacks
27 PCR04837 TX 4 100 % 75 % 75 % B 0 % 0 % US-born
28 PCR00041 TX 13 31 % 69 % 69 % H 0 % 31 % none
29 PCR02397 GA 11 100 % 91 % 100 % B 18 % 64 % US-born Blacks
30 PCR00293 GA 16 100 % 56 % 100 % B 44 % 56 % US-born Blacks
31 PCR01571 GA 8 25 % 38 % 88 % A 0 % 88 % none
32 PCR00002 GA 5 0 % 40 % 100 % A 0 % 60 % Foreign-born Asians (but country mixture)
33 PCR04200 MD 4 0 % 50 % 100 % H 0 % 75 % Mexico-born Hispanics
34 PCR01017 MD 4 0 % 50 % 100 % H 0 % 50 % Foreign-born Hispanics (but country mixture)
35 PCR00002 MD 12 0 % 67 % 100 % A 0 % 0 % Foreign-born Asians (but country mixture)
36 PCR00016 MA 10 100 % 100 % 50 % B 100 % 100 % Homeless US-born males
37 PCR01034 MA 3 33 % 100 % 100 % B 100 % 0 % Homeless Black males
38 PCR00002 MA 13 8 % 54 % 92 % A 8 % 0 % none
39 PCR00051 TX 29 72 % 69 % 52 % H 14 % 31 % none
40 PCR01873 TX 3 100 % 100 % 100 % B 0 % 67 % US-born Black males
41 PCR00036 TX 8 100 % 100 % 75 % B 13 % 0 % US-born males
42 PCR03588 GA 6 100 % 100 % 100 % B 33 % 83 % US-born Black males
43 PCR00017 GA 4 100 % 75 % 100 % B 50 % 50 % US-born Blacks
44 PCR00015 GA 15 100 % 47 % 87 % B 7 % 40 % US-born
aMost common race/ethnicity: A-Asian, B-Black/African American, H-Hispanic, W-non-Hispanic white/Caucasian
bPercent of patients with an epidemiologic link to another patient with a concordant PCRType
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Among 388 study patients having contact investigation
(CI) records available, CI record review (Step 2) found
15 (3.9 %) linked patients. Patients without CI records
(n = 63, 16.2 %) were associated with having only extra-
pulmonary TB manifestations, or being homeless or in-
jection drug users (p < 0.05). A total of 3893 contacts
were evaluated with a median of five contacts per pa-
tient. CI outcomes included 687 (17.6 %) individuals
with LTBI, 286 (7.3 %) with prior LTBI, 81 (2.1 %) with
active TB disease and the remaining 2839 having no TB
history, but associated with the study patient. In
reviewing the public health records (Step 3) of patients
with no epidemiologic link found in Steps 1–2, 41/281
(14.6 %) linked patients were identified. CLI interviews
(Step 4) were completed on 30 % (119/401) of patients
with 28/119 (23.5 %) linked patients found (Fig. 2).
Among patients who did not have CLI interviews,
27.0 % (76/282) had epidemiologic link(s) that had
already been identified through Steps 1–3. The patients
had decreased odds for CLI interviews if they were
homeless (p < 0.001), male (p < 0.001) or age 65 or older
and increased odds for CLI interviews if they were diag-
nosed after 2008 (p < 0.001) or were from the MD site
(p = 0.047) (data not shown).
Among 201 linked patient-pairs, 188 (93.5 %) pairs
had concordant PCRTypes and 13 (6.5 %) pairs had dis-
cordant PCRTypes (66 and 62 % with definite linkage
strength, respectively; p = 0.7). All of the 13 linked
patient-pairs with discordant PCRTypes had discordant
MIRU12 patterns (median of three discordant loci),
while seven also had discordant spoligotypes. These 13 ge-
notypically discordant, but epidemiologic-linked, patient-
pairs were excluded from further consideration because
their high level of discordance suggested that the linked
patient-pairs were not part of the same transmission
chain. The 188 linked patient-pairs with concordant
PCRTypes corresponded to only 179 of the 401 study
patients (45 %) having epidemiologic links because 75
patients had more than one link identified.
Specific transmission venues were identified for some
clusters. Among 19 clusters with at least three pairs of
epidemiologic-linked patients (Clusters 01, 02, 08, 10,
11, 12, 13, 14, 16, 20, 23, 24, 28, 29, 30, 31, 36, 39 and 42),
11 (57.9 %) had at least 50 % of their total epidemiologic
links associated with a specific venue: four with homeless
shelters (Clusters 01, 12, 23 and 36), three with drug
houses (Clusters 16, 30 and 42), two with churches
(Clusters 14 and 31), one with a bar (Cluster 39) and
another with a social club (Cluster 24). Over 90 % of
epidemiologic links identified for Clusters 01, 23 and
36 were associated with homeless shelter transmission
venues. All epidemiologic links identified for Cluster 42
were associated with a drug house venue and seven of
the eight (88 %) epidemiologic links identified for Cluster
24 were associated with a social club transmission venue.
Seven (37 %) of the 19 clusters with at least three pairs of
epidemiologic-linked patients were mainly (≥50 %) associ-
ated with household or non-household close social trans-
mission venue (Clusters 02, 08, 10, 13, 20, 28, and 29).
Among 16 epidemiologic linked pairs of the remaining
Fig. 2 Patient enrollment and study procedures for cluster investigation
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cluster (Cluster 11), seven (44 %) was associated with
homeless shelters and four (25 %) was associated with a
church.
There was substantial variability by cluster in terms of
the proportion of patients with identified epidemiologic
links (Table 2, “Epi-linked” column), ranging from 0 to
100 %. No epidemiologic links were identified for pa-
tients in 13/44 (30 %) clusters, despite having all four
CLI steps completed on 36 % of the 77 patients in these
clusters. The number of clusters having all black patients
was significantly lower in 13 clusters without epidemiologic
links than in those with epidemiologic links [2 (15.4 %)
versus 15 (48.4 %), p = 0.040]. No difference in the number
of clusters having 100 % foreign-born patients was seen
between the two groups (data not shown).
Twenty-five percent of epidemiologic links from HOU
were identified through CLI. Meanwhile, epidemiologic
links from MA and MD had lower odds of being identified
by CLI TB patient interviews than linkages from other sites
(Table 3; p = 0.004 and p = 0.036, respectively). All epidemi-
ologic links with a household transmission setting and/or
involving relatives were identified earlier than Step 4, while
workplace and church transmission settings were associ-
ated with identification through CLI TB patient interviews
in Step 4 (p = 0.032 and p = 0.046, respectively). Epidemio-
logic links involving a black TB patient had higher odds of
being identified by early investigation steps (p = 0.036). Epi-
demiologic links including Asians or patients with extra-
pulmonary TB were associated with identification through
CLI TB patient interviews in univariate analysis (p < 0.001
and p = 0.033, respectively); these associations became
non-significant in multivariate results. Definite (strength)
epidemiologic links had decreased odds for identification
through interviews (p < 0.007) (Table 3). All epidemiologic
links identified for clusters 14, 19, and 43 were identified
by CLI TB patient interviews and over 50 % of links identi-
fied for clusters 31 and 39 were identified by CLI TB pa-
tient interviews (Data not shown).
Discussion
Contact investigation of individuals who had contact
with TB patients is a cornerstone of public health TB
control [1]. However, limitations of the concentric circle
approach to contact investigations have been highlighted
by reports of TB transmission not found through tradi-
tional contact investigation methods [11, 23–26]. In our
study, a considerable number of additional linked patients
(n = 28; 14.8 % of all identified patients with at least one
link to another person in the cluster) found in the CLI
interview were not identified through the previous CI
(Fig. 2).
Molecular epidemiologic data suggests that routine con-
tact investigations, targeting household, work, and school
contacts, commonly miss other locations where infectious
TB patients spend time and transmit disease, especially
leisure or social settings [11, 17, 27, 28]. The CDC contact
investigation guidelines [1] recommend collecting infor-
mation on potential transmission settings during patient
CI interview. In the absence of named TB patient con-
tacts, location-based information on possible transmission
venues collected routinely during patient interviews can
be useful in establishing relationships between genotypi-
cally linked TB patients [11].
By looking for homogeneity within a cluster using rou-
tinely collected surveillance data, we were able to generate
characteristic profiles for many clusters. These cluster-
specific epidemiologic profiles provided hints into poten-
tial transmission venue types for given clusters and pro-
vided insight into questions to ask, or locations to look for
while seeking epidemiologic linkages during CLI steps.
CLI steps were prioritized to minimize resources re-
quired to uncover epidemiologic links by first asking health
department staff who were directly involved in the TB pa-
tient’s care if they were aware of links to other patients
(Step 1). When applied in a local health department con-
text, existing knowledge of clusters or patient relationships
is available through communication with a case manager,
disease intervention specialist, or contact investigator
(public health workers). Existing contact investigation
records were then reviewed for documented links (Step 2).
The next investigation step, entailing review and evaluation
of public health records, added a more time-intensive and
analytic component to investigations (Step 3). Finally, the
most resource intensive step was patient re-interviews
(Step 4). The analysis of the CLI step where epidemiologic
links were determined (Table 3) demonstrated various
scenarios where CLI interviews had added utility compared
to earlier investigative steps. Higher odds of epidemiologic
links were found in association with workplace, when pa-
tient-pairs resided in different zip codes within the
same jurisdiction and Asian or African American pa-
tients (Table 3). Although we found 11 study participants
having unknown epidemiologic links through contact in-
vestigation review (Step 2), we do not know how many
contacts with active TB had epidemiologic links because a
contact with active TB might be involved in more than
one epidemiologic link.
Limitations to this study include the possibility of not
including all patients in a potential genotype cluster
given genotype coverage during the study period (espe-
cially for GA and HOU), the inability to locate and obtain
consent from patients for re-interviews and exclusion of
clinically defined and non-genotyped culture-positive pa-
tients with epidemiologic links to patients in study clus-
ters. In addition, the infectious period of each patient was
not considered. Although beyond the scope of this
study, including non-genotyped patients may show a
more complete picture of cluster transmission dynamics.
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Table 3 Characteristics associated with epidemiologic links being identified by CLI TB patient interviews (Step 4) versus earlier in CLI
(Steps 1–3)
Epi-linked patient-pairs with concordant PCRTypes Unadjusted Adjusteda
Identified without CLI TB
patient interviews (n = 158)
Identified by CLI TB
patient interviews (n = 30)
OR p-value 95 % CI OR p-value 95 % CI
Study site, n (%)
Texas (City of Houston) 45 (28.5 %) 15 (50.0 %) 2.51 0.226 0.57, 11.16 0.20 0.191 0.02, 2.25
Massachusetts 26 (16.5 %) 2 (6.7 %) 0.36 0.218 0.07, 1.82 0.04 0.004 0.00, 0.35
Maryland 48 (30.4 %) 1 (3.3 %) 0.08 0.050 0.01, 1.00 0.01 0.036 0.00, 0.73
Georgia 39 (24.7 %) 12 (40.0 %) 2.03 0.357 0.45, 9.22 –
Race/ethnicity, n (%)
Asian 4 (2.5 %) 5 (16.7 %) 7.70 <0.001 3.12, 19.00 0.28 0.349 0.02, 4.07
Black 93 (58.9 %) 6 (20.0 %) 0.18 0.010 0.05, 0.66 0.21 0.036 0.05, 0.90
Hispanic 32 (20.1 %) 13 (43.3 %) 3.01 0.211 0.53, 16.97 –
White 24 (10.8 %) 6 (10.0 %) 1.11 0.889 0.25, 4.94 –
Transmission setting, n (%)
Household 29 (18.4 %) 0 (0.0 %) NA –
Close social 27 (17.1 %) 2 (6.7 %) 0.35 0.147 0.08, 1.45 –
Workplace 5 (3.2 %) 4 (13.3 %) 4.71 0.015 1.36, 16.35 7.16 0.032 1.19, 43.08
Shelter 58 (36.7 %) 4 (13.3 %) 0.27 0.139 0.05, 1.54 –
Church 5 (3.2 %) 8 (26.7 %) 11.13 0.051 0.99, 125.43 10.98 0.046 1.04, 116.08
Drug house 17 (10.8 %) 2 (6.7 %) 0.59 0.579 0.09, 3.76 –
Other 17 (10.8 %) 10 (33.3 %) 0.24 0.047 0.06, 0.98 0.25 0.024 0.08, 0.83
Relationship between case pairs, n (%)
Relative 25 (15.8 %) 0 (0.0 %) NA –
Friend 41 (26.0 %) 4 (13.3 %) 0.44 0.204 0.12, 1.56 –
Coworker 4 (2.5 %) 4 (13.3 %) 5.92 0.008 1.58, 22.27 –
Genotype lineage, n (%)
East Asian (L2) lineage 30 (19.0 %) 12 (40.0 %) 2.84 0.118 0.77, 10.54 0.98 0.976 0.19, 5.07
Euro-American (L4) lineage 122 (77.2 %) 18 (60.0 %) 0.44 0.229 0.12, 1.67 –
Common genotype in US†, n (%) 8 (5.1 %) 2 (6.7 %) 1.34 0.709 0.29, 6.21 –
Extra-pulmonary only site of TB,
n (%)
8 (5.1 %) 6 (20.0 %) 4.69 0.033 1.13, 19.42 9.54 0.105 0.62, 146.32
US-birth, n (%) 132 (83.5 %) 24 (80.0 %) 0.79 0.739 0.19, 3.21 –
HIV infection, n (%) 54 (34.2 %) 6 (20.0 %) 0.48 0.301 0.12, 1.92 –
Incarcerated at TB diagnosis,
n (%)
10 (6.3 %) 1 (3.3 %) 0.51 0.567 0.05, 5.10 –
Homeless, n (%) 83 (52.5 %) 8 (26.7 %) 0.33 0.136 0.08, 1.42 –
Excess alcohol use, n (%) 112 (70.9 %) 15 (50.0 %) 0.41 0.146 0.12, 1.37 –
Non-injection drug use, n (%) 70 (44.3 %) 8 (26.7 %) 0.46 0.058 0.20, 1.03 0.48 0.118 0.19, 1.21
Patient pairs with different zip
codes in same jurisdiction, n (%)
99 (66.9 %) 22 (88.0 %) 3.63 0.022 1.21, 10.89 2.84 0.174 0.63, 12.83
Patient pairs from different
jurisdictions, n (%)
10 (6.3 %) 5 (16.7 %) 2.96 0.103 0.81, 10.89 4.41 0.070 0.89, 21.95
Epidemiologic link strength =
“definite”, n (%)
114 (72.2 %) 10 (33.3 %) 0.19 <0.001 0.08, 0.45 0.22 0.007 0.22, 43.23
OR odds ratio, CI confidence interval, CLI cluster investigation
aAdjusted in the multivariate model. The final model included study site, race/ethnicity, transmission setting, genotype lineage, TB site, non-injection drug use,
pairs with different zip codes in same jurisdiction, pairs from different jurisdictions and definite epi-link link strength
†PCRTypes associated with > 400 TB patients in the U.S. 2006-2010 and reported in > 40 states (PCR00002, PCR00015, PCR00022, PCR00041)
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Furthermore, NTGS transitioned from using spoligotype
and 12-locus MIRU-VNTR (MIRU12) to spoligotype and
24-locus MIRU-VNTR (MIRU24) in 2009 to increase the
discriminatory power of MIRU-VNTR [8, 14, 15]. Since
this study was initiated in 2009 and included cases in pre-
vious years, cluster definition and selection process had to
be defined by spoligotype and MIRU12. Given the variant
number of epidemiologic links identified by different
study sites, interview style (although standardized) may
have played a role in potentially influencing subjective and
qualitative outcomes. Despite the variation of results seen
between sites, one of our study outcomes was to provide
additional high-risk TB contacts identified by CLIs. In
resource-limited jurisdictions where local funding and re-
source may not be enough to launch the cluster investiga-
tions, the information of high-risk contacts that were
missed by the initial CIs is still helpful for evaluation pur-
poses and to help TB programs improve their conven-
tional CI techniques. Lastly, recall bias could not be ruled
out, especially in patients who were diagnosed with TB
many years before their cluster investigation interview was
conducted.
Public health departments need to develop strategies and
focus resources to prioritize and investigate clusters that
may be of public health concern. An initial step in these in-
vestigations should be to evaluate clusters using readily
available data. Many data elements needed to investigate
clusters in specific jurisdictions are now available to TB
control personnel routinely and electronically through the
Tuberculosis Genotyping Information Management Sys-
tem [19]. Additionally, the 2009 expansion of the RVCT
includes up to two state case numbers for TB patients
epidemiologic-linked to the reported patient [22], so health
departments can easily assess clusters for epidemiologic
links. If the transmission dynamics are poorly understood
and the cluster continues to grow, additional resources
should be devoted to the CLI, including abstracting public
health records of clustered patients and interviewing the
TB patients to find epidemiologic linkages between pa-
tients beyond those identified by the health department. As
we found in this study, re-interviewing patients in a cluster
(Step 4), especially when no epidemiologic links have been
identified can facilitate the identification of transmission
venues and locations that are crucial in interrupting the
ongoing transmission and cluster growth. Further study on
improving the interviewing methods may be needed to in-
crease the detection rate of epidemiologic links in Mtb
genotype clusters. In addition, CI record review (Step 2)
found 15 (3.9 %) linked patients exemplifying a need for
better tools and trainings for contact investigations, which
is an essential component of TB control programs.
Despite the continuing decline in US TB rates leading to
a decrease of funding for public health activities for TB con-
trol, the elimination goals established in 1989 [29] remain
unmet. With the recent leveling rates of TB [30], an inter-
ruption of the Mtb transmission by implementing the ex-
panded and efficient CIs and CLIs would be critical for the
success of TB control and prevention programs in the US.
Conclusion
We validated a practical method to systematically
identify tuberculosis epidemiologic links that can be
integrated into routine TB control and prevention pro-
grams in public health settings. Re-interviewing pa-
tients in a cluster can identify additional epidemiologic
links that were not found in the previous CLI steps.
Improvement of the interview methods and effective
contact investigation trainings may be needed as no
epidemiologic links were identified in one-third of the
Mtb genotype clusters.
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